VANCOUVER, British Columbia, Oct. 28 /PRNewswire/ -- enGene Inc., an emerging leader in the field of protein therapeutics, announced today that Frost & Sullivan has awarded the company its 2005 Excellence in Research of the Year Award for development of its innovative Gut Endocrine-cell Modification System (GEMS(TM)) for application in the field of protein therapeutics in diabetes.
Frost & Sullivan presents the Award each year to a company that has pioneered an innovative technology that is “disruptive” to the status quo and has demonstrated a strong commitment to its development. This Award recognizes technologies that are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award also recognizes the research excellence of a company and the significance of the research to the overall industry.
“Receiving the prestigious Frost & Sullivan Award supports our vision to be a leader in creating and delivering innovative solutions to unmet medical needs using proprietary technologies,” said Eric A. Adams, President and CEO of enGene.
enGene’s GEMS(TM) is a proprietary technology designed to induce certain cells in the intestinal tract to produce a wide range of therapeutic protein drugs to treat several diseases including diabetes, obesity, hemophilia, inflammatory bowel disease and anemia. In diabetes, this technology has the potential to eliminate the dependency on external insulin by re-enabling the human body to produce insulin and release it, in the proper quantity and at the appropriate time, to regulate blood glucose levels.
“enGene is honored to have been chosen for this Award as we continue to make significant progress towards human clinical trials for type I diabetes, the first of many applications for this platform technology,” said Dr. Anthony T. Cheung, Chief Scientific Officer of enGene, who will accept the Award on November 9 in Miami. “We are pleased to see our GEMS(TM) technology gaining recognition for its therapeutic promise from researchers, investors, potential commercial partners and now by an industry-leading market research firm.”
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com .
About enGene Inc.
enGene Inc. is a privately held biotechnology company developing a proprietary technology that offers a unique therapeutic solution to treating metabolic diseases such as diabetes and obesity as well as other diseases caused by protein insufficiency. Our initial product, GEMS(TM) for diabetes (GEMS(TM)-insulin), is in the pre-clinical phase. GEMS(TM) for obesity is in the discovery phase, as is GEMS(TM) for hemophilia. enGene holds broad and exclusive patent protection for its technologies.
This release and additional information about enGene Inc. are also available on the Internet at: www.engeneinc.com.
Certain statements in this press release may constitute “forward-looking statements” of enGene within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
enGene Inc.
CONTACT: enGene Inc., +1-604-221-4362, or info@engeneinc.com